Abstract
Congenital lipodystrophy is a rare genetic disorder characterized by a near-complete absence of fat cells, hypoleptinemia leading to a voracious appetite, and marked insulin resistance. This article focuses on the known cardiovascular manifestations of patients with congenital lipodystrophy, including cardiomyopathy, cardiac arrhythmias, and accelerated atherosclerosis arising from a markedly deranged metabolic milieu. Future research that targets leptin deficiency (metreleptin) and apoC3 mRNA (antisense oligonucleotide) could open a window for potential pharmacological treatment of this challenging disorder.
Original language | English (US) |
---|---|
Pages (from-to) | 181-186 |
Number of pages | 6 |
Journal | Clinical Diabetes |
Volume | 34 |
Issue number | 4 |
DOIs | |
State | Published - 2016 |
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism